This is an open-label, single-center Phase 0/2 study that will enroll up to 30 participants
with newly diagnosed (N=12) and recurrent glioblastoma (N=18). The trial will be composed of
a Phase 0 component (subdivided into Arm A, Arm B, and Arm C), and an Exploratory Phase 2
component. Participants with tumors demonstrating a PK response in the Phase 0 component of
the study will graduate to an exploratory Phase 2 component that combines therapeutic dosing
of pamiparib plus fractionated radiotherapy (for unmethylated MGMT promoter newly-diagnosed
cases), pamiparib plus fractionated radiotherapy (for recurrent cases) or Olaparib plus
fractionated radiotherapy (recurrent cases).
Phase:
Early Phase 1
Details
Lead Sponsor:
Nader Sanai
Collaborators:
Barrow Neurological Institute BeiGene Ivy Brain Tumor Center